Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             19 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A randomised phase III study of bevacizumab and carboplatin–pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial Felip, E.

36 5 p. 548-560
artikel
2 Comment on: A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial Meyer, J.

36 5 p. 601
artikel
3 Editorial Board
36 5 p. iii
artikel
4 Efficacy assessment in phase I clinical trials: endpoints and challenges Gouda, M.A.

36 5 p. 507-519
artikel
5 Enhancing radiotherapy with PARP inhibition in soft-tissue sarcomas: a promising synergy requiring specific attention to normal tissues? Levy, A.

36 5 p. 488-490
artikel
6 FOxTROT: is anti-EGFR a good dancing partner? Montagut, C.

36 5 p. 475-477
artikel
7 Going forward in pleural mesothelioma: time for a shift from a single-entity treatment approach Hayashi, H.

36 5 p. 478-480
artikel
8 Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆ Vogel, A.

36 5 p. 491-506
artikel
9 Lessons from TROPiCS-04: ‘safety-first’ for success in late-stage clinical trials Ong, M.

36 5 p. 481-483
artikel
10 Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population ☆ Seligmann, J.F.

36 5 p. 520-528
artikel
11 Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials Dal Pra, A.

36 5 p. 572-582
artikel
12 Reply to Letter to the Editor: ‘A phase III randomised trial on the addition of a contact x-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 years results of the OPERA trial’ by J. Meyer, T. Koessler Baron, D.

36 5 p. 601-602
artikel
13 Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib Horinouchi, H.

36 5 p. 583-591
artikel
14 Results of a phase Ib study of olaparib with concomitant radiotherapy in soft-tissue sarcoma: a French sarcoma group study Sargos, P.

36 5 p. 592-600
artikel
15 Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial Powles, T.

36 5 p. 561-571
artikel
16 Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials Williams, H.

36 5 p. 543-547
artikel
17 Table of Contents
36 5 p. i-ii
artikel
18 Telisotuzumab vedotin and osimertinib: the METamorphosis of epidermal growth factor receptor-mutant lung cancer? Remon, J.

36 5 p. 484-487
artikel
19 The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study Rangelova, E.

36 5 p. 529-542
artikel
                             19 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland